Karyopharm flags a PhII overall survival failure for lead drug selinexor in acute myeloid leukemia
Investigators for Karyopharm $KPTI say that it’s clear at the interim analysis stage that its lead drug selinexor has failed a Phase II test for overall survival in acute myeloid leukemia.
The company called it after finding that 13% in the selinexor arm demonstrated a complete response with or without full hematologic recovery, compared to 3% of patients on the physician’s choice control arm. And those complete responders will have a chance to continue treatment with the drug.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
